

New Grant Focuses on Medical Fitness to Drive in Aging

If you live long enough, chances are that changes in your health &/or functional status will require you to retire from driving. For persons diagnosed with Alzheimer's disease (AD), it is not a question of if retirement from driving will be required, but *when*.

Concerned family members often turn to physicians and other health providers for answers. Few physicians have specific training in this area, however, and it can take time for patients, families and health providers to agree on an appropriate course of action.

A new 2-year ADRC project funded by the American Automobile Association (AAA) Foundation for Traffic Safety will explore this situation from the perspective of driver licensing in Missouri. Education Core Leader, Dr. Tom Meuser, will serve as Principal Investigator and Coordinator of the project, entitled *Medical Fitness to Drive & A Voluntary State Reporting Law*.

Two other Washington University faculty, Drs. David Carr (Medicine/Geriatrics) and Gudmundur Ulfarsson (Civil Engineering) will participate significantly in the project. Other co-investigators include Marla Berg-Weger, PhD (Saint Louis University), Pat Niewoehner, OTR/L, CDRS (St. Louis VAMC), & Peggy Barco, MS, OTR/L (Center for Head Injury Services).

In 1998, through a joint lobbying effort of the AAA, Concerned Americans for Responsible Driving, Alzheimer's Association, Washington University, and other organizations, the Missouri Legislature passed a voluntary reporting law for potentially unsafe drivers. House Bill 1536 allows physicians, other health professionals, law enforce-

Left to right:
Tom Meuser,
PhD, David
Carr, MD, &
Gudmundur
Ulfarsson,
PhD.



ment and license office personnel, social service professionals, family members, and others to report potentially unsafe drivers for retesting and possible license revocation (see www.drivingsafe.org). The law grants immunity from prosecution for breach of confidentiality, is non-specific with regards to age (although the majority of those reported are older), and includes a Medical Advisory Board for review of complex cases. HB-1536 is administered through the Drivers License Bureau, Missouri Department of Revenue (MDOR), in cooperation with the Missouri State Highway Patrol (MSHP) which provides all on-road testing.

Most individuals reported under HB-1536 are asked to submit a physician's statement documenting their health status. Depending on what's in this report, some may be required to take on-road testing through the Highway Patrol, while others may lose the privilege to drive immediately.

A State-University Partnership

Although 43 of 50 states in the US have voluntary reporting laws like HB-1536, to date, none of these laws have been evaluated for efficacy. Do such laws actually remove unsafe drivers from the road? What medical conditions are of the greatest concern?

With strong support from officials at MDOR and MSHP, Dr. Meuser, Dr. Carr, and the rest of the team will gather the data necessary to

answer these and other important questions.

Since 1999, over 7,000 individuals have been reported under the provisions of HB-1536. Thousands of professional and family reports and health statements are available for analysis. These data will be combined with citation records (e.g., speeding tickets, moving violations) and crash data to provide a comprehensive characterization of the medically impaired older driver in Missouri. Updates will be provided in future issues of *HORIZONS*.

Norman R. Seay Lecture Announced

On Tuesday, September 19th, 12-1 PM, the ADRC will honor long-time friend and supporter, Norman R. Seay, with the first of an annual series of lectures.

Mr. Seay is a renowned civil rights leader, retired University of Missouri—St. Louis administrator, and President of the Federation of Block Units, an affiliate of the St. Louis Urban League. Since 2001, he has served with distinction as the Chair of the ADRC's African American Advisory Board. We are grateful for his encouragement, insight, and service.

Jennifer Manly, PhD, Assistant Professor of Neuropsychology in Neurology at the G.H. Sergievsky Center and the Taub Institute for Research in Aging and Alzheimer's Disease at Columbia University, will be the first Norman R. Seay lecturer.



Call 314-286-0930 for details.

A Short, Valid Assessment for Dementia?

One of the many exciting projects underway at the ADRC focuses on developing a brief, valid, and culturally appropriate screening tool to detect dementia in the community. Starting in 2004, Center Director, Dr. John C. Morris, and colleagues, have worked to develop and validate such a tool, called the Brief Inventory for Dementia Detection (BIDD). The BIDD includes questions for a family informant and specific tests for the person with suspected dementia. Preliminary validation data suggests that the BIDD works. Those found to have a score in the impaired range go on to receive a dementia diagnosis following a more detailed clinical assessment.

Validation of the BIDD involves fruitful collaborations with Saint Louis University (SLU) and the St. Louis County Health Department (SLCHD). Participants from a SLU Study—*Physical Frailty in Urban African Americans*—are administered the BIDD along with a more detailed assessment at our Center. Through the dedicated efforts of MAP nurse clinician, Pamela Jackson, physicians and nurses from the SLCHD are learning to administer the BIDD as part of care they provide to older adults in our community. Data from both of these collaborative efforts will confirm the validity and cultural sensitivity of this new screening tool.

Pamela Jackson, RN, BSN, MA



"I have met a lot of interesting people and the staff at both facilities are very helpful. It appears health literacy is a big problem and the community is not informed about this devastating disease that robs the mind. Some perceive Washington University as not being community oriented, however most individuals I meet are appreciative of the information I am share and willing to learn about the ADRC."

Fellow Profile

Yuan-Han "John" Yang, MD, PhD, a Neurologist from Taiwan, joined the ADRC as a *Visiting Research Scholar* last Fall, and he will work with our team through 2006. Dr. Yang is interested in risk factors for Alzheimer's disease and is pursuing a number of projects in this area.



In His Own Words:

Since 1993, when I was a medical student, I worked with Dr. Ching-Kuan, Liu, Professor of Neurology, Kaohsiung Medical University, to investigate the prevalence of dementia in Taiwan. I visited thousands of people during that investigation each year. Instead of being tired, I felt I should help people from such disease if I could.

Once I graduated with my MD degree, I entered the Graduate Institute of Medicine for my PhD degree to continue my way and mission of working for people suffering from dementia.

Fortunately, under kindly approve of Dr. Morris, I got the opportunity to visit ADRC to continue my study. I also deeply appreciate my parents, wife, Tiffany, kids, and all colleagues at Taiwan Dementia Society.

Given all of your help, I can continue my mission, and moreover, I can and should work with ADRC against dementia because we are the world and it is time to give our hands to life.

Volunteers Needed for ADRC Studies

Do you know of someone that might consider volunteering for a research project on cognitive aging?

Two primary projects of the ADRC are in need of new volunteers this year. The **Memory & Aging Project** enrolls persons aged 65+ with mild memory problems. The **Adult Children Study** needs a few additional adult volunteers, age 55 or older, with a family history of Alzheimer's disease (AD) in at least one parent, as well as adult volunteers 45 and older for whom neither parent had AD.

If you know of a potential volunteer, please ask that person to call the ADRC at 314-286-2863. Thank you!

HORIZONS is the newsletter of the **Alzheimer's Disease Research Center (ADRC)** — a research program in the Department of Neurology, Washington University School of Medicine, funded by grants from the National Institute on Aging and private donations. The ADRC supports and promotes interdisciplinary research on Alzheimer's Disease. The Memory & Aging Project (MAP) — the clinical research office of the ADRC — provides expert clinical assessments of cognitive functioning in normal aging and dementia.

Alzheimer's Disease Research Center

4488 Forest Park Avenue, Suite 130
St. Louis, MO 63108

ADRC (314) 286-2881; MAP (314) 286-2683

<http://alzheimer.wustl.edu> / adrcedu@abraxas.wustl.edu

John C. Morris, MD, Director, ADRC, & Director, MAP
Eugene M. Johnson, PhD, Associate Director, ADRC
David M. Holtzman, MD, Associate Director, ADRC
Martha Storandt, PhD, Psychometric Core Leader
Nigel J. Cairns, PhD, MRCPATH, Neuropathology Core Leader
Alison Goate, DPhil, Genetics Core Leader
Mark Mintun, MD, & Denise Head, PhD, Neuroimaging Core Leaders
J. Philip Miller, MA, Biostatistics Core Leader
Dorothy F. Edwards, PhD, African American Satellite Leader
Thomas M. Meuser, PhD, Education Core/Rural Satellite Leader

 **Washington University in St. Louis**
SCHOOL OF MEDICINE

Brain scan, cerebrospinal fluid analysis may help predict Alzheimer's

A combination of brain scanning with a new imaging agent and cerebrospinal fluid (CSF) analysis has left neuroscientists encouraged that they may finally be moving toward techniques for diagnosing Alzheimer's disease before its clinical symptoms become apparent.

"When clinical symptoms start, the disease process has already been at work in the patient for many years and possibly even decades," explains Anne Fagan Niven, Ph.D., research associate



Dr. Anne Fagan

professor of neurology at Washington University School of Medicine in St. Louis. "Up to 30 percent of neurons in vulnerable areas are already dead, and you can't get them back. So finding markers that can help us identify patients prior to symptoms is really our big push now."

With colleagues Mark Mintun, M.D., professor of radiology, and David Holtzman, M.D., the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology, Fagan studied a group of 24 people that included individuals diagnosed with very mild and mild Alzheimer's disease and cognitively normal subjects. As expected, in patients with cognitive impairments believed to be attributable to Alzheimer's disease, researchers found low CSF levels of amyloid beta 42 (A-beta 42), the principal ingredient of the brain plaques that are characteristic of Alzheimer's disease. In the same individuals, brain scans with a new imaging agent that reveals the presence of amyloid plaques in the brain were positive.

What scientists didn't anticipate was that three cognitively normal subjects would have both low CSF levels of A-beta 42 and positive results from the brain scans. Fagan stressed that although this aspect of their findings was very intriguing, it doesn't prove that the three normal subjects will one day develop clinical Alzheimer's disease.

"For now, definitive diagnosis of Alzheimer's disease still cannot be made until autopsy," she says. "It's going to take a number of years for us to fully assess these results, because all we can do now is follow the participants closely to see if they eventually develop Alzheimer's dementia."

Fagan presented the result of the study at the November 2005 annual meeting of the Society for Neuroscience in Washington, D.C. The study also appeared in the March 2006 issue of *Annals of Neurology*.

Selected as a "Paper of the Week" by the Alzheimer Research Forum, an independent, nonprofit, internet-based resource on AD research.

<http://www.alzforum.org/>

Many prior studies have found that A-beta 42 levels drop in the cerebrospinal fluid of Alzheimer's disease patients. A-beta 42 is naturally produced in the brain, and researchers suspect that the creation of amyloid plaques may be linked to breakdowns of the processes that normally clear A-beta 42 from the brain via the CSF and the bloodstream.

However, natural variations occur in CSF A-beta 42 levels in healthy subjects, and the amount this level drops in Alzheimer's patients also varies. This left no distinct level scientists could identify as a diagnostic marker characteristic of Alzheimer's disease.

Fagan wanted to see if useful distinctions could be made by combining data on CSF A-beta 42 levels with results from brain scans with a new imaging agent, PIB (for Pittsburgh compound B). Developed by researchers at the University of Pittsburgh, PIB temporarily sticks to amyloid plaques in the brain but washes clean in 30 to 60 minutes. Scientists can detect this sticking with a PET scanner.

Using PIB data available from ongoing studies of research volunteers at the Memory and Aging Project at the Alzheimer's Disease Research Center at Washington

University, Fagan compared PIB scan results and levels of CSF A-beta 42.

"When I realized that everyone who was PIB positive also had lower CSF A-beta 42 levels, I had one of those 'aha!' moments that makes it so exciting to be a scientist," Fagan says.

Other CSF factors, such as levels of another form of A-beta and of a molecule found in the brain cell tangles created by Alzheimer's disease, did not correlate with positive PIB scan results.

Story by Michael Purdy, Medical Public Affairs, Washington University School of Medicine.

Brain Donation

Did you know that over 60% of MAP-ADRC participants agree to donate their brains to science upon death? Brain autopsy is the one sure way to confirm a dementia diagnosis given in life.

At Washington University, our specialists can diagnose Alzheimer's disease (AD) with ~93% accuracy. Other forms of dementia are more challenging to get right, however. The autopsy plays a critical role in the research process, paving the way for studies connecting data collected in life with confirmed diagnoses. Many studies, in fact, now require the use of autopsy-confirmed cases.



The final act of volunteering for research on AD is brain donation. We are deeply grateful to our participants and their family members for supporting this aspect of the research process. *Family members play an especially important role, as they are responsible for notifying the Center of the death within a few hours and working with our Autopsy Nurse to make sure the process goes smoothly.*

If you haven't decided on brain donation as yet, please consider this possibility. Call 314-286-2683 if you have any questions about the autopsy process. Thank you.



Genetics & AD:

Understanding Individual Risk

A Community Program

11:30 AM—2 PM
Wednesday, 8/23/06

Where?

Central Reform Congregation
5020 Waterman Avenue
St. Louis, MO 63108

Sponsors?

- ♦ Washington University ADRC
- ♦ Alzheimer's Association

Topics?

- ♦ Basics of Alzheimer's Disease
- ♦ Concepts in Human Genetics
- ♦ Genetics of Alzheimer's
- ♦ Understanding Individual Risk

RSVP?

Call 800-980-9080 to reserve your seat for this program. Cost = \$10. All attendees will receive a box lunch. Call early to hold a seat!

Become ADRC Friend

Would you like to make a gift in support of the ADRC? You may support our research, education and service goals by joining the *Friends of the ADRC*. Members of the *Friends* are entitled to attend periodic *Friends Receptions* featuring presentations on research findings from Dr. John C. Morris, Director of the ADRC, and other investigators, and also receive free admission to various ADRC-sponsored conferences. *Friends* are encouraged to make an annual gift in support of the ADRC.

Donations from *Friends* support both the infrastructure upon which the ADRC depends, as well as specific research and educational projects of the Center. Private donations help to fund promising pilot research projects (i.e., small projects to test out new ideas), educational conferences such as the Leonard Berg Symposium series, the training of medical students and fellows, and other worthwhile projects.

To join, simply call (314-286-241) or e-mail (adrcfriends@abraxas.wustl.edu) the *Friends Coordinator*.

Participant Profile – Ella Marie Bolden Brown

by Pamela Jackson, RN, BSN, MA

The ADRC Family would like to acknowledge one of our participants for her numerous achievements.

My first encounter with Mrs. Ella Bolden Brown was in 2004 when she called to ask about participating in our Memory & Aging Project (MAP). She was knowledgeable about dementia because her sister had been diagnosed previously with Alzheimer's disease. She wanted to participate in research to learn and help others. Once the criteria were explained, she agreed to participate without hesitation. The requirement for lumbar puncture (spinal tap) didn't bother her in the least. "I'll do all that I can to know the why, what and how of Alzheimer's disease," she commented.



Born in Fort Worth, Texas, she eventually relocated to St. Louis, in part to escape the effects of racism. Apparently she was *programmed for education* and decided to pursue a career in nursing. Mrs. Brown's knowledge, skills, and abilities have enabled her to be the first black person to be inducted into the *Missouri Nurses Association Hall of Fame*. This awards ceremony was held April 8, 2006, at the Forest Park Golf Clubhouse Restaurant.

As I summarize her history, it is no surprise that she was also chosen as a *Lifetime Achiever in Health Care* by the St. Louis American Newspaper in 2005. A graduate of Homer G. Phillips Nursing School in 1947, Mrs. Brown has been instrumental in educating hundreds of nurses in our community. After receiving her diploma, she continued her educational quest by attending Saint Louis University, receiving her Bachelors in Nursing in 1950. She later attended Washington University and received a Masters degree in Nursing in 1980. She also attended Webster University in the 80's and graduated with a Masters in Health Facilities Management. Prior to retiring in 1984, she served as Executive Assistant to the Hospital Commissioner for the City of St. Louis.

Mrs. Brown was a trailblazer at Homer G. Phillips and City Hospital. In addition to her accomplishments at these institutions, she has also served as President, Vice President, Chair, Vice Chair, etc., of numerous organizations and committees. To highlight all her accomplishments would take many pages—space I don't have here. I would like to mention a few more outstanding contributions:

- Homer G. Phillips Nurse Alumni
- Board of Directors for People's Clinic
- One of the first black nurses to run for President, MO Nurses Association
- Recognition from Saint Louis University as an *Integration Pioneer*
- *Longevity Award* for Adult Basic Education
- *Top Ladies of Distinction Mother of the Year*
- One of the founders of the St. Louis Chapter Black Nurses Association
- Member of Celebrity Seniors - Saint Louis Connect Care
- Member of Alpha Kappa Alpha Sorority
- Mentor St. Louis Participant
- Founding member, local chapter, Sigma Theta Tau Nursing Honor Society
- 1998 *Volunteer Award* Recipient from KSDK Channel 5

A member of Antioch Baptist Church since 1944, Mrs. Brown continues as an active participant in the Sunday School Department, Chancel Choir, Memorial Choir, and Women's Missionary Union.

These are just a few accomplishments of this outstanding octogenarian. Mrs. Brown states that despite all the accomplishments and leadership roles, her most cherished roles were that of a wife, mother, grand mother and great grand mother. The support she received from her family has allowed her to reach for the stars and achieve so much success!

Benzodiazepine Use in the Aging Population

Millions of prescriptions are written each year in the US for benzodiazepines. Those who take medications in this class (see list below) need to know about side effects and alternatives. This article provides a brief summary.

Brand / Trade Name	Generic Name
Ativan	lorazepam
Xanax	alprazolam
Valium	diazepam
Klonopin	clonazepam
Restoril	temazepam
Halcion	triazolam
Serax	oxazepam
Dalmane	flurazepam
Librium	chlordiazepoxide
Tranxene	clorazepate

Why are these drugs prescribed?

Benzodiazepines are prescribed most often for anxiety and insomnia problems. The risk of experiencing one of these conditions may increase as we age. Benzodiazepines are indicated for short-term control of these conditions, commonly defined as no more than 10 days with the first attempt to control symptoms and no more than four months on the second attempt to control symptoms. Longer-term use may be appropriate in some instances.

How do benzodiazepines work?

These drugs work within the central nervous system, that is, the brain and spinal cord. They mimic the action of a neurotransmitter which is in charge of depressing certain areas of the central nervous system to produce feelings of relaxation and drowsiness. They are efficacious when used for the correct indication, with the appropriate dosage, and under the supervision of the doctor.

What are the common side effects?

Because these drugs work to depress the brain and spinal cord, patients may experience effects

such as:

- ◆ Decreased mental alertness
- ◆ Drowsiness, Confusion
- ◆ Blurred Vision
- ◆ Impaired Judgment
- ◆ Dizziness, Disorientation
- ◆ Depression, Emotional Problems
- ◆ Impaired Learning & Recall
- ◆ General Forgetfulness
- ◆ Uncontrolled Muscle Movements
- ◆ Addiction / Withdrawal

Are they safe for older adults?

Benzodiazepines can cause and/or worsen cognitive problems, especially in older adults. Memory loss is a common side effect. Even though every individual taking this medication will not experience side effects, it is important to realize that they can occur and the elderly are more susceptible to experiencing them. Recent studies indicate that cognitive impairment may also develop gradually as a late complication of long-term benzodiazepine use. Most experts agree that benzodiazepines should be avoided in patients with memory loss or dementia.

What about negative drug interactions?

Benzodiazepines interact negatively with a number of medications used by older adults. Alcohol use can worsen such interactions even further. For example, Digoxin is a drug commonly prescribed for heart failure, and when taking it simultaneously with a benzodiazepine, the level of Digoxin in the blood may increase resulting in toxic effects. Other drugs that may interact with benzodiazepines are:

Barbiturates	Propranolol
Narcotics	Scopolamine
Cimetidine	Theophylline
Oral Contraceptives	Levodopa
Prozac (fluoxetine)	Ketoconazole
Probenicid	Valproic Acid
Ranitidine	Metoprolol
Isoniazid	Darvocet

Specific brands may have different drug interactions. Consult your doctor or pharmacist to learn more.

Are there any medical conditions that are adversely affected by benzodiazepines?

In addition to memory loss and dementia, benzodiazepines may be harmful for persons with respiratory/lung diseases, such as chronic obstructive pulmonary disease (COPD), bipolar mood or addiction disorders, closed angle glaucoma, hepatic or renal impairment, Parkinson's disease, and certain seizure disorders.

Are there any alternatives for anxiety / insomnia?

Benzodiazepines differ in the ways they are metabolized in the body. Lower doses of oxazepam, lorazepam, and temazepam are safer in the elderly population than other benzodiazepines. Ambien (zolpidem) is an alternative that may have fewer side effects.

However, the safest alternative would be nonpharmacologic, behavioral measures. For controlling insomnia, such measures include avoiding substances that can affect alertness / drowsiness at bedtime (caffeine, alcohol, nicotine, stimulants), establishing a regular time to wake up and go to sleep, avoiding naps during the day, avoiding excessive fullness or hunger before bed, and creating a comfortable sleep environment. For controlling anxiety, nonpharmacologic measures include exercising regularly, avoiding stimulants like caffeine, eating a well balanced diet, meditating, and avoiding alcohol.

Lastly, many medications have side effects or drug interactions which result in anxiety or insomnia. The first thing a person should do when experiencing one of these symptoms is to check with a doctor or pharmacist to see if the anxiety or insomnia may be a result of a medication he or she is currently taking.

A special contribution from Laura Reukert, Pharm.D, a recent graduate of the St. Louis College of Pharmacy. Ms. Reukert produced this summary as part of a dementia elective during her last semester.

Aging, Healthcare & Dementia in Rural Missouri

by Tom Meuser, PhD

Missouri is a rural State in terms of geography and population distribution. According to the Office of Social and Economic Data Analysis (OSED), University of Missouri, 91 of Missouri's 113 counties are considered rural/non-metropolitan by US Census criteria. A meaningful portion of Missouri's population in 2000 (32%) resided in these 91 rural counties. Four metropolitan areas (St. Louis, Kansas City, Columbia, Springfield—where our four Alzheimer's Association chapters are based) and nearby areas accounted for the majority of state residents (68%).

Missouri's total population of older adults in 2000 was 13.5%, higher than the national average of 12.4%. A substantial number of households in rural counties included one or more older adults. As shown in Figure 1, the rural counties of north central and south central Missouri had particularly high percentages (dark blue, up to 41%) of elder households in 2000.

Why is this? According to OSED, overall population in many rural counties declined over the past 20 years. One explanation is that older




Figure 1

adults are “aging in place” whereas younger adults are moving elsewhere and fewer children are born to remaining residents. Adults aged 85 and over, in fact, represented the second highest growing population group in Missouri (next to baby boomers aged 35-54) between 1990 and 2000. The number of older adults in this 85+ cohort rose 21.4% during this period.

Although a substantial number of older adults reside in rural counties, relatively few physicians practice in these counties. Only 16% of all licensed physicians in Missouri practiced in rural counties in 2000. Rural Knox County in northeastern Missouri (circled in red in Figure 1), for example, had a total population of 4,300 when the census was taken in 2000, with 21% of residents over the age of 65 years. Only five licensed physicians practiced in Knox County at that time!

In Knox County, as in probably most rural counties across the US, older adults must often travel many miles to other counties or metropolitan areas to access healthcare services. This situation is likely to complicate care for older adults with Alzheimer's disease (AD) who must rely on others (family, friends, social service organizations) to facilitate and otherwise follow-up on medical appointments and general care needs.

Approximately one third of Missouri's estimated 125,000 persons with AD reside in rural counties. Changing demographics suggest that a substantial portion of these live alone, and thus may face even greater healthcare challenges.

What's being done?

Community service organizations, such as the Alzheimer's Association and Area Agencies on Aging, are doing a lot to serve the needs of rural elders. Rural hospitals, such as Audrain Medical Center in Mexico, Missouri, serve as important hubs for dementia care, drawing patients from many miles.

The Washington University ADRC supports rural dementia care through educational outreach. Our *Rural Clinician Partners Program* (RCPP) seeks to improve dementia care in rural areas by enhancing the knowledge base of the physicians and other healthcare professionals that practice there.

The RCPP uses a “mini-residency” educational model, involving select groups of clinicians in 3-day inten-

sive training experiences in St. Louis. Many ADRC faculty and staff volunteer their time and expertise to participate in RCPP sessions — provided to small groups of 4-5 trainees up to six times per year.

Primary care physicians, advanced practice nurses, and physician assistants are the primary targets for the program. Clinicians may apply for entry, or individuals may be nominated by a colleague, local organization, or even a patient.

Since 2000, the RCPP has trained over 85 clinicians from across Missouri. As shown in Figure 2 below, trainees have come from rural counties across the state (red stars). Counties in cream have just 8-102 persons per square mile. For comparison, St. Louis County has over 2,000 persons per square




Figure 2

mile. The counties of far northwest and west central Missouri are important RCPP targets for the next few years.

Initial planning is underway for the ADRC to co-sponsor a *Rural Dementia Care* conference in the Spring of 2008. The goal of the conference will be to document the challenges associated with providing quality dementia care in rural areas and to propose practical improvements. More details will follow in future issues of *HORIZONS*.

COMING SOON
Missouri Senior Report 2006
A Joint Project of OSEDA & Aging
Organizations across Missouri
Obtain your copy at:
www.oseda.missouri.edu

Informational Table – Active Clinical Trials through MAP-ADRC (May, 2006)

Investigational Agent	Inclusion Criteria	Exclusion Criteria	Exclusionary Meds	Study Design	Refer patients to:
<p>AAB-201 Phase II of Passive Immunization Trial Participants receive 6 infusions (every 13 weeks and 5 MRI's) Follow-up for this study will likely be several years.</p>	<p>50-85 years old. Alzheimer's Disease. Lives at home with family co-participant. 3 month stable dose of AD treatment.</p>	<p>Weight greater than 264lbs. Clinically significant infection in the last 30 days. MI in the last 2 years. Cancer within last 5 yrs. Smoking more than 20cigs/day. Clinically evident stroke.</p>	<p>Systemic steroids Anticonvulsants PD medications Anticoagulants Narcotics Nonprescription meds for cognition. Medication that may affect cognition.</p>	<p>Safety and Efficacy Study. There is a placebo group. Follow-up is over 2 years. At least 5 MRI scan are done over the course of the study.</p>	<p>Christy Tomlinson MSN, RN Study Coordinator 314-286-2364 tomlinsonc@abraxas.wustl.edu enrollment ongoing</p>
<p>Namenda Study Not actually drug study. Observing brain changes of people on Aricept/Namenda by MRI. NO PLACEBO Group.</p>	<p>50-80 years old. Alzheimer's disease. Must be on stable dose of Aricept. Memantine to be added. Participants receive Namenda (Memantine) at no cost for the 2 years of the study.</p>	<p>Unable to have MRI History of LOC or other neurologic disorder that would confound dementia assessment.</p>		<p>Persons with mild to moderate AD will be enrolled. Need to be on Aricept. Memantine (Namenda) to be started. MRI scan done before start of Memantine and at the end of study. Participants have cognitive testing once every 3 months for 2 year. Memantine is provided at no cost.</p>	<p>Wendy Overkamp, BA Study Coordinator 314-286-1971 overkampw@abraxas.wustl.edu enrollment ongoing</p>
<p>LY450139 Gamma Secretase Inhibitor Trial</p>	<p>Age 50 and above. Women – post menopausal Mild AD. Excellent health. Stable dose of standard AD treatment for 4 months. Reliable caregiver.</p>	<p>Non English speaking History of peptic ulcer disease or GI bleed. History of decreased renal function History of Cancer within 5 years.</p>	<p>Antipsychotics MAOI inhibitors Benzodiazepines Calcium channel blockers Immunosuppressants Macrolide antibiotics BusPar, Dapsone, Methadone, Inderal, Advair.</p>	<p>Study is Double-Blind. Placebo control (:1) lasting 29 weeks. Monitoring visits 2 weeks for the first 14 weeks. Lumbar puncture done at beginning of study and at end of treatment phase of study. One visit is 6 hours long as multiple blood samples obtained.</p>	<p>Angela Oliver, MSG, RN Study Coordinator 314-286-2407 olivera@abraxas.wustl.edu enrollment ongoing</p>
<p>LZAJ Phase IIa of Passive Immunization Trial</p>	<p>Age 50 and above. Women – post menopausal Mild AD. Excellent health. Stable dose of standard AD treatment for 4 months. Reliable caregiver</p>	<p>Non English speaking Not able to have MRI (claustrophobia, metal implants or pacemaker). Not able to have lumbar puncture. Other neurodegenerative or infectious brain disease. Allergy to antibodies History of cancer, drug or alcohol abuse within 5 years.</p>	<p>Antipsychotics: Phenothiazines, Loxapine, Molidone, Pimozide, Tiethixene Other medications which affect nervous system must be of stable dose for 4 months.</p>	<p>Placebo controlled; double blind study. Year long study. IV drug administered every week for 12 doses then follow-up at intervals until completion of the study. MRI of Brain X3 over course of study Lumbar Puncture done at beginning of study and end of treatment phase.</p>	<p>Study Coordinators: Pam Millisap MSN, RN 314-286-2363 or Mary Coats 314-286-2303 Enrollment started 5/1/06</p>

New Faces



Benita Austin, MSN, APRN-BC, ANP, joined MDC as a nurse clinician in April. Prior, she managed bone marrow transplant care at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine in Baltimore.



Karolina K. Piotrowicz joined MAP as a clerk in January. A native of Poland and an accomplished linguist, Karolina is working towards her BA in Managerial Economics. She and her husband, Jarek, will soon celebrate their first wedding anniversary.



Joy Kurz, MSN, RN, GNP-BC, joined MAP and MDC as a nurse clinician in April. Prior, she served as Director of the Senior Care/Wound Care Center at Des Peres Hospital. Joy also has a criminal justice degree and worked as a juvenile probation officer years ago.



Sherry Ellis joined MAP as a secretary in February. Prior to starting at Washington University four years ago, Sherry worked in the travel industry. A native of St. Louis with her husband, a pet supply salesman, she keeps busy raising three teenagers.



Abbey DeWeese joined MAP as a psychometrician in May. Abbey just received her BA in Psychology from UM-St. Louis and hopes to eventually pursue a PhD. Right now, much of her energy is devoted to her young daughter, Corrine, and getting ready for a June wedding.



Jessica C. Lester will join the ADRC as a project coordinator in July. She received her BA in Sociology from the University of Chicago in 2003, hopes to attend medical school in the future. Her fiancé, Kevin Germino, is a Pediatric Resident at SLU.

Fond Farewells

Ebru Karakoc, MD, Fellow — Returned to Turkey to complete her residency in Neurology.

Linda Ding, Psychometrician — Starts Medical School at the University of Missouri-Columbia in July.

Angie Berry, MSN, Nurse Clinician — Joined the Human Studies Committee as a Senior Research Review Specialist.

Lea Grinberg, MD, PhD, Fellow — Returned to Brazil to open a Neuropathology Lab at the University of Sao Paulo.

Rajka Liscic, MD, PhD, Fulbright Fellow — Returned to Croatia to continue her career as an academic neuroscientist.



4488 Forest Park Avenue
Suite 130
St. Louis, MO 63108
(314) 286-2881; 286-2683; Fax 286-2763
<http://alzheimer.wustl.edu>
adrcedu@abraxas.wustl.edu

NONPROFIT ORG.
U.S. POSTAGE
PAID
St. Louis, MO
PERMIT NO. 4453